Angiogenic growth factors and hypertension

Angiogenesis

Volumn 7, Issue 3, 2004, Pages 193-201

  Sane, David C ^a   Anton, Lauren ^a   Brosnihan, K Bridget ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Hypertension; Pre eclampsia; Rarefaction; Vascular endothelial growth factor

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ADRENOMEDULLIN; ANGIOGENIC FACTOR; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN[1-7]; ANGIOTENSINOGEN; ANGIOTENSINOGEN DERIVATIVE; BEVACIZUMAB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR 2; LOSARTAN; PLACENTAL GROWTH FACTOR; QUINAPRILAT; SCATTER FACTOR; SOMATOMEDIN C; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VATALANIB;

ANGIOGENESIS; ANTIHYPERTENSIVE ACTIVITY; ATHEROSCLEROSIS; HUMAN; HYPERTENSION; ISCHEMIA; KIDNEY CARCINOMA; LUNG EDEMA; MICROALBUMINURIA; MICROVASCULATURE; NONHUMAN; PATHOGENESIS; PREECLAMPSIA; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASOMOTOR REFLEX;

ANGIOGENIC PROTEINS; ANIMALS; FEMALE; HUMANS; HYPERTENSION; KALLIKREINS; MICE; NEOVASCULARIZATION, PATHOLOGIC; PRE-ECLAMPSIA; PREGNANCY; RENIN-ANGIOTENSIN SYSTEM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 12444304260     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10456-004-2699-3     Document Type: Review

References (129)

1. Kiefer FN, Neysari S, Humar R et al. Hypertension and angiogenesis. Curr Pharm Des 2003; 9: 1733-44.
2. Greene, AS. Microvascular regulation and dysregulation. In Izzo JL, Black HR (eds) Hypertension Primer, 3rd edition. Philadelphia: Lippincott Williams & Wilkins 2003; 183-5.
3. Koller A. Signaling pathways of mechanotransduction in arteriolar endothelium and smooth muscle cells in hypertension. Microcirculation 2002; 9: 277-94.
4. Hutchins PM, Darnell AE. Observation of a decreased number of small arterioles in spontaneously hypertensive rats. Circ Res 1974; 34: I161-5.
5. Hansen-Smith FM, Morris LW, Greene AS et al. Rapid microvessel rarefaction with elevated salt intake and reduced renal mass hypertension in rats. Circ Res 1996; 79: 324-30.
6. Noon JP, Walker BR, Webb DJ et al. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest 1997; 99: 1873-9.
7. Antonios TFT, Rattray FM, Singer DRJ et al. Rarefaction of skin capillaries in normotensive offspring of individuals with essential hypertension. Heart 2003; 89: 175-8.
8. Sullivan JM, Prewitt RL, Josephs JA. Attenuation of the microcirculation in young patients with high-output borderline hypertension. Hypertension 1983; 5: 844-51.
9. Gasser P, Buhler FR. Nailfold microcirculation in normotensive and essential hypertensive subjects, as assessed by video-microscopy. J Hypertens 1992; 10: 83-6.
10. Henrich HA, Romen W, Heimgartner W et al. Capillary rarefaction characteristic of the skeletal muscle of hypertensive patients. Klin Wochenshrift 1998; 66: 54-60.
11. Prasad A, Dunnill GS, Mortimer PS et al. Capillary rarefaction in the forearm skin in essential hypertension. J Hypertension 1995; 13: 265-8.
12. Sonntag WE, Lynch CD, Cooney PT et al. Decreases in cerebral microvasculature with age are associated with the decline in growth hormone and insulin-like growth factor 1. Endocrinology 1997; 138: 3515-20.
13. Khan AS, Lynch CD, Sane DC et al. Growth hormone increases regional coronary blood flow and capillary density in aged rats. J Gerontol Ser A, Biol Sci Med Sci 2001; 56: B364-71.
14. Edelberg TM, Reed MJ. Aging and angiogenesis. Front Biosci 2003; 8: s1199-209.
15. Hutchins PM, Lynch CD, Cooney PT et al. The microcirculation in experimental hypertension and aging. Cardiovasc Res 1996; 32: 772-80.
16. Vasan RS, Beiser A, Seshadri S et al. Residual lifetime risk for developing hypertension in middle-aged women and men. JAMA 2002; 287: 1003-10.
17. Ku DD, Zaleski JE, Liu S, Brock TA. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol 1993; 265: H586-92.
18. Laham RJ, Li J, Tofukuji M et al. Spatial heterogeneity in VEGF-induced vasodilation: VEGF dilates microvessels but not epicardial and systemic arteries and veins. Ann Vasc Surg 2003; 17: 245-52.
19. Henry TD, Annex BH, McKendall GR et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 2003; 107: 1359-65.
20. Cuevas P, Carceller F, Ortega S et al. Hypotensive activity of fibroblast growth factor. Science 1991; 254: 1208-10.
21. Unger EF, Goncalves L, Epstein SE et al. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. Am J Cardiol 2000; 85: 1414-9.
22. Laham RJ, Chronos NA, Pike M et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a phase I open-label dose escalation study. J Am Coll Cardiol 2000; 36: 2132-9.
23. Simons M, Annex BH, Laham RJ et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: Double-blind, randomized, controlled clinical trial. Circulation 2002; 105: 788-93.
24. Keiser JA, Ryan MJ. Hemodynamic effects of epidermal growth factor in conscious rats and monkeys. Proc Natl Acad Sci USA 1996; 93: 4957-61.
25. Jin H, Yang R, Li W et al. Early treatment with hepatocyte growth factor improves cardiac function in experimental heart failure induced by myocardial infarction. J Pharmacol Exp Ther 2003; 304: 654-60.
26. Ebeling PR, Jones JD, O'Fallon WM et al. Short-term effects of recombinant human insulin-like growth factor I on bone turnover in normal women. J Clin Endocrin Metab 1993; 77: 1384-7.
27. Lainchbury JG, Troughton RW, Lewis LK et al. Hemodynamic, hormonal, and renal effects of short-term adrenomedullin infusion in healthy volunteers. J Clin Endocrinol Metab 2000; 85: 1016-20.
28. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovas Res 2001; 49: 568-81.
29. Chavakis E, Dimmeler S. Regulation of endothelilal cell survival and apoptosis during angiogenesis. Arterioscler Thromb Vasc Biol 2002; 22: 887-93.
30. Dimmeler S, Fisslthaler B, Fleming I et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399: 601-5.
31. Hood JD, Meininger CJ, Ziche M et al. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998; 274: H1054-8.
32. Cooke JP. NO and angiogenesis. Atherosclerosis Supplements 2003; 4: 53-60.
33. Ziche M, Morbidelli L, Choudhuri R et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced buy not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997; 99: 2625-34.
34. Murohara T, Asahara T, Silver M et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 1998; 101: 2567-78.
35. Shizukuda Y, Tang S, Yokota R et al. Vascular endothelial growth factor-induced endothelial cell migration and proliferation depend on a nitric oxide-mediated decrease in protein kinase Cδ activity. Circ Res 1999; 85: 247-56.
36. He H, Venema VJ, Gu X et al. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through Flk-1/KDR activation of c-Src. J Biol Chem 1999; 274: 25130-5.
37. Jin Z-G, Ueba H, Tanimoto T et al. Ligand-independent activation of vascular endothelial growth factor receptor 2 by fluid shear stress regulates activation of endothelial nitric oxide synthase. Circ Res 2003; 93: 354-63.
38. v integrins. Science 1995; 270: 1500-10.
39. 3 integrin mediates arteriolar vasodilation in response to RGD peptides. Circ Res 1996; 79: 821-6.
40. Shyy JYJ, Chien S. Role of integrins in endothelial mechanosensing of shear stress. Circ Res 2002; 91: 769-75.
41. Wang Y, Miao H, Li S et al. Interplay between integrins and FLK-1 in shear stress-induced signaling. Am J Physiol Cell Physiol 2002; 283: C1540-7.
42. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. NEJM 2003; 349: 427-34.
43. Cobleigh MA, Langmuir VK, Sledge GW et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Seminars in Oncology 2003; 30(Suppl 16): 117-24.
44. Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-7.
45. Thomas AL, Morgan B, Drevs J et al. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin Oncol 2003; 30(suppl 6): 32-8.
46. Felmeden DC, Spencer CG, Belgore FM et al. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens 2003; 16: 11-20.
47. Nakamura S, Moriguchi A, Morishita R et al. A novel vascular modulator, hepatocyte growth factor (HGF), as a potential index of the severity of hypertension. Biochem Biophys Res Commun 1998; 242: 238-43
48. Nakao-Hayashi J, Ito H, Kanayasu T et al. Stimulatory effects of insulin and insulin-like growth factor I on migration and tube formation by vascular endothelial cells. Atherosclerosis 1992; 92: 141-9.
49. Nicosia RF, Nicosia SV, Smith M. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. Am J Pathol 1994; 145: 1023-9.
50. Delafontaine P, Song Y-H, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol 2004; 24: 1-10.
51. Díez J. Insulin-like growth factor I in essential hypertension. Kidney Int 1999; 55: 744-59.
52. Cottone S, Vadalá A, Mangano MT et al. Endothelium-derived factors in microalbuminuric and nonmicroalbuminuric essential hypertensives. Am J Hypertens 2000; 13: 172-6.
53. Bagnato A, Spinella F. Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab 2003; 14: 44-50.
54. Goumans M-J, Lebrin F, Valdimarsdotti G. Controlling the angiogenic switch. A balance between two distinct TGF-β receptor signaling pathways. Trends Cardiovasc Med 2003; 13: 301-7.
55. 1 in essential hypertension. Am J Hypertens 2002; 15: 207-11.
56. 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci USA 2000; 97: 3479-84.
57. 1 levels in hypertensive patients: association with body mass index and leptin. Am J Hypertens 2002; 15: 759-65.
58. Lijnen PJ, Petrov VV, Fagard RH. Association between transforming growth factor-β and hypertension. Am J Hypertens 2003; 16: 604-11.
59. De Matteo R, May CN. Direct coronary vasodilator action of adrenomedullin is mediated by nitric oxide. Br J Pharmacol 2003; 140: 1414-20.
60. Zhao Y, Hague S, Manek S et al. PCR display identifies tamoxifen induction of the novel angiogenic factor adrenomedullin by a non estrogenic mechanism in the human endometrium. Oncogene 1998; 16: 409-15.
61. Kato J, Kitamura K, Matsui E et al. Plasma adrenomedullin and natriuretic peptides in patients with essential or malignant hypertension. Hypertens Res 1999; 22: 61-5.
62. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet 2001; 357: 53-6.
63. Maynard SE, Min JY, Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. JCI 2003; 111: 649-58.
64. Tsatsaris V, Goffin F, Munaut C et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: Pathophysiological consequences. J Clin Endocrine Metab 2003; 88: 5555-63.
65. Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. New Engl J Med 2004; 350: 672-83.
66. Luttun A, Carmeliet P. Soluble VEGF receptor Flt1: The elusive preeclampsia factor discovered? JCI 2003; 111: 600-2.
67. Solomon CG, Seely EW. Preeclampsia - searching for the cause. New Engl J Med 2004; 350: 641-2.
68. Cross MJ, Dixelius J, Matsumoto T et al. VEGF-receptor signal transduction. Trends Biochem Sci 2003; 28: 488-94.
69. Robelink TJ, de Boer HC, de Koning EJP, van Zonneveld A-J. Endothelial progenitor cells: More than an inflammatory response? Arterioscler Thromb Vasc Biol 2004; 24: 834-8.
70. Zheng W, Sefton EA, Meininger CJ et al. Mechanisms of coronary angiogenesis in response to stretch: Role of VEGF and TGF-β. Am J Physiol 2001; 280: H909-17.
71. Feng Y, Yang JH, Huang H et al. Transcriptional profile of mechanically induced genes in human vascular smooth muscle cells. Circ Res 1999; 85: 1118-23.
72. Chang H, Shyu K-G, Wang B-W et al. Regulation of hypoxia-inducible factor-1α by cyclical mechanical stretch in rat vascular smooth muscle cells. Clin Sci 2003; 105: 447-56.
73. Kuwahara F, Kai H, Tokuda K et al. Hypoxia-inducible factor-1 α/1 vascular endothelial growth factor pathway for adventitial vasa vasorum formation in hypertensive rat aorta. Hypertension 2002; 39 46-50.
74. Safran M, Kaelin, Jr. WG. HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 2003; 111: 779-83.
75. Chua CC, Hamdy RC, Chua BH. Upregulation of vascular endothelial growth factor by anigiotensin II in rat heart endothelial cells. Biochim Biophys Acta 1998; 1401: 187-194.
76. Williams B, Baker AQ, Gallacher B et al. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 1995; 25: 913-7.
77. Yang R, Ogasawara AK, Zioncheck TF et al. Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats. Hypertension 2002; 39: 815-20.
78. Senger Dr, Perruzzi CA, Feder J et al. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986; 46: 5629-32.
79. Lenfant C, Roccella EJ. A call to action for more aggressive treatment of hypertension. J Hypertens 1999; 17(Suppl 1): S3-7.
80. Heistad DD, Lawton WJ, Talman WT. Pathogenesis of acute hypertension encephalopathy. In Izzo JL, Black HR (eds) Hypertension Primer, 3rd edition. Philadelphia: Lippincott Williams & Wilkins 2003; 201-3.
81. Schoch HJ, Fischer S, Marti HH. Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain 2002; 125: 2549-57.
82. Josko J, Knefel K. The role of vascular endothelial growth factor in cerebral oedema formation. Folia Neuropathol 2003; 41: 161-6.
83. Jensen JS, Borch-Johnsen K, Jensen G et al. Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. Clin Sci (Colch) 1995; 88: 629-33.
84. Mor F, Quintana FJ, Cohen IR. Angiogenesis-inflammation cross-talk: Vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization. J Immunol 2004; 172: 4618-23.
85. Kim I, Moon S-O, Kim SH et al. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-κB activation in endothelial cells. J Biol Chem 2001; 276: 7614-20.
86. Arisato T, Hashiguchi T, Sarker KP et al. Highly accumulated platelet vascular endothelial growth factor in coagulant thrombotic region. J Thromb Haemost 2003; 1: 2589-93.
87. Shen BQ, Lee DY, Cortopassi KM et al. Vascular endothelial growth factor KDR receptor signaling potentiates tumor necrosis factor-induced tissue factor expression in endothelial cells. J Biol Chem 2001; 276: 5281-6.
88. Eremina V, Sood M, Haigh J, et al Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal disease. J Clin Invest 2003; 111: 707-16.
89. Bortoloso E, Prete D, Vestra M et al. Quantitate and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type 2 diabetes. Eur J Endocrinol 2004; 150: 799-807.
90. Eremina V, Sood M, Haigh J et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal disease. J Clin Invest 2003; 111: 707-16.
91. Asselbergs FW, deBoer RA, Diercks GFH et al. Vascular endothelial growth factor: the link between cardiovascular risk factors and microalbuminuria? Int J Cardiol 2004; 93: 211-5.
92. Santilli F, Spagnoli A, Mohn A et al. Increased vascular endothelial growth factor serum concentrations may help identify patients with onset of Type I diabetes during childhood at risk for developing persistent microalbuminuria. J Clin Endocrinol Metab 2001; 86: 3871-6.
93. Cottone S, Vadalá A, Mangano MT et al. Endothelium-derived factors in microalbuminuric and nonmicroalbuminuric essential hypertensives. Am J Hypertens 2000; 13: 172-6.
94. Cooper LT, Hiatt WR, Creager MA et al. Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication. Vasc Med 2001; 6: 235-9.
95. Vasan RS, Beiser A, Seshadri S et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002; 287: 1003-10.
96. Scheubel RJ, Zorn H, Silber RE et al. Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 2003; 42: 2073-80.
97. Goodman-Gruen D, Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study Am J Epidemiol 1997; 145: 970-6.
98. Harris TB, Kiel D, Roubenoff R et al. Association of insulin-like growth factor-I with body composition weight history, and past health behaviors in the very old: the Framingham Heart Study. J Am Ger Soc 1997; 45: 133-9.
99. Dimmeler S, Vasa-Nicotera M. Aging of progenitor cells: Limitation for regenerative capacity? J Am Coll Cardiol 2003; 42: 2081-2.
100. Emanueli C, Salis MB, Stacca T et al. Angiotensin AT1 receptor signaling modulates reparative angiogenesis induced by limb ischemia. Br J Pharmacol 2002; 135: 87-92.
101. Munzemaier DH, Greene AS. Opposing actions of antgiotensin II on microvascular growth and arterial blood pressure. Hypertension 1996; 27: 760-5.
102. Le Noble FA, schreurs NH, van Straaten HW et al. Evidence for a novel angiotensin II receptor involved in angiogenesis in chick embryo chorioallantoic membrane. Am J Physiol 1993; 264: R460-5.
103. Fernandez LA, Twickler J, Mead A. Neovascularization produced by angiotensin II. J Lab Invest Clin 1985; 105: R141-5.
104. Page EL, Robitaille GA, Poussegur J et al. Induction of hypoxia-inducible factor-1α by transcriptional and translational mechanisms. J Biol Chem 2002; 277: 48403-9.
105. Otani A, Takagi H, Suzuma K, Honda Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 1998; 82: 619-28.
106. Amaral SL, Linderman JR, Morse MM et al. Angiogenesis induced by electrical stimulation is mediated by angiotensin II and VEGF. Microcirculation 2001; 8: 57-67.
107. Stoll M, Steckelings UM, Paul M et al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95: 651-7.
108. Sasaki K, Murohara T, Ikeda H et al. Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. J Clin Invest 2002; 109: 603-11.
109. Toko H, Zou Y, Minamino T et al. Angiotensin II type 1a receptor is involved in cell infiltration, cytokine production, and neovascularization in infarcted myocardium. Arterioscler Thromb Vasc Biol 2004; 24: 664-70.
110. Volpert OV, Ward WF, Lingen MW et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996; 98: 671-9.
111. Silvestre JS, Tamarat R, Senbonmatsu T et al. Antiangiogenic effect of angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb. Circ Res 2002; 90: 1072-9.
112. Benndorf R, Böger RH, Ergün S et al. Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells. Circ Res 2003; 93: 438-47.
113. Levy BI. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 2004; 109: 8-13.
114. Walther T, Menrad A, Orzechowski H et al. Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J 2003; 17: 2061-7.
115. De Gaspara M, Catt KJ, Inagami T et al. International union of pharmacology. XXXII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-72.
116. Ferrario CM, Brosnihan KB, Diz DI et al. Angiotensin-(1-7): A new hormone of the angiotensin system. Hypertension. 1991; 18(Suppl 5): 126-33.
117. Freeman EJ, Chisolm GM, Ferrario CM et al. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 1996; 28: 104-8.
118. Zeng W, Hong MA, Wang L et al. The role of angiontensin-(1-7) in the proliferative response of vascular smooth cells induced by endothelin-1. Chin J Geriatr Cardiovasc Cerebrovasc Dis 2001; 3: 107-9.
119. Strawn WB, Ferrario CM, Tallant EA. Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 1999; 33: 207-11.
120. Machado RD, Santos RA, Andrade SP. Opposing actions of angiotensins on angiogenesis. Life Sci 2000; 66: 67-76.
121. Machado RD, Santos RA, Andrade SP. Mechanisms of angiotensin-(1-7)- induced inhibition of angiogenesis. Am J Physiol Regul Integr Comp Physiol. 2001; 280: R994-1000.
122. Cameron NE, Cotter MA, Robertson S. Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats. Diabetologia 1992; 35: 12-18.
123. 2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats. Hypertension. 1997; 29: 478-82.
124. Fabre JE, Rivard A, Magner M et al. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation 1999; 99: 3043-49.
125. Kokkonen JO, Lindstedt KA, Kuoppala A et al. Kinin-degrading pathways in the human heart. Trends Cardiovasc Med 2000; 10: 42-5.
126. 2 receptor pathway. Circ Res 2001; 89: 678-83.
127. Celerier J, Cruz A, Lamande N et al. Angiotensinogen and its cleaved derivatives inhibit angiogenesis. Hypertension 2002; 39: 224-28.
128. Tewksbury D. Angiotensinogen: Biochemistry and molecular biology. In Laragh JH, Brenner GM (eds) Hypertension. New York: Raven Press 1990; 1197-216.
129. Colman RW, Jameson BA, Lin Y et al. Domain 5 of high molecular weight kininogen (kinostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood 2000; 95: 543-50.